Caligan Partners LP — 13F Holdings & Portfolio

CIK 1727492 · latest 13F-HR filed 2026-08-14

Caligan Partners LP manages $2.13B in 13F-reported U.S. long-equity assets across 28 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are LQDA (30.45%), RVMD (17.28%), ABVX (9.77%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 5 new positions, exited 4, added to 13, and trimmed 4.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Filer Information
Address
780 THIRD AVENUE
30TH FLOOR
NEW YORK, NY 10017
Phone
(718) 570-6018
Filing Manager
Caligan Partners LP
NEW YORK, NY
Signatory
Tiffany Crowley
Chief Financial Officer/Chief Compliance Officer
Loading holdings…
AUM

$2.13B

Long-equity book

Holdings

28

Distinct positions

Period

2026-06-30

Filed 2026-08-14

Q/Q Activity

+5 / −4 / ↑13 / ↓4

vs 2026-03-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • LIQUIDIA CORPORATION$340.9M +111.3%
  • REVOLUTION MEDICINES INC$206.7M +128.6%
  • ABIVAX SA$44.8M +27.5%
  • AVALO THERAPEUTICS INC$34.1M +139.5%
  • AURA BIOSCIENCES INC$29.0M +1884.5%
Show all 13

Top Trims

  • XENON PHARMACEUTICALS INC-$27.3M -33.7%
  • TYRA BIOSCIENCES INC-$23.1M -47.3%
  • MBX BIOSCIENCES INC-$14.3M -56.4%
  • OPUS GENETICS INC-$2.7M -9.6%
Show all 4

New Positions

  • IMMUNOCORE HLDGS PLC$43.9M
  • VIRIDIAN THERAPEUTICS INC$40.3M
  • SAGIMET BIOSCIENCES INC$19.3M
  • ARTIVA BIOTHERAPEUTICS INC$16.8M
  • CELLECTAR BIOSCIENCES INC$1.3M
Show all 5

Exited Positions

  • MINERALYS THERAPEUTICS INC$75.1M
  • SPYRE THERAPEUTICS INC$44.3M
  • MAZE THERAPEUTICS INC$18.4M
  • XILIO THERAPEUTICS INC$943.0K
Show all 4
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 LIQUIDIA CORPORATION LQDA 53635D202 $647.3M 30.45% 8,118,892 SH
2 REVOLUTION MEDICINES INC RVMD 76155X100 $367.4M 17.28% 1,961,795 SH
3 ABIVAX SA ABVX 00370M103 $207.6M 9.77% 1,557,924 SH
4 VAXCYTE INC PCVX 92243G108 $127.2M 5.99% 2,188,636 SH
5 EXELIXIS INC EXEL 30161Q104 $84.5M 3.98% 1,553,262 SH
6 TANGO THERAPEUTICS INC TNGX 87583X109 $78.2M 3.68% 2,500,103 SH
7 AVALO THERAPEUTICS INC AVTX 05338F306 $58.5M 2.75% 3,163,866 SH
8 XENON PHARMACEUTICALS INC XENE 98420N105 $53.7M 2.53% 889,944 SH
9 ADMA BIOLOGICS INC ADMA 000899104 $47.9M 2.25% 5,725,007 SH
10 REVOLUTION MEDICINES INC Call RVMD 76155X100 $47.2M 2.22% 251,800 SH
11 LB PHARMACEUTICALS INC LBRX 50180M108 $46.7M 2.20% 1,438,070 SH
12 IMMUNOCORE HLDGS PLC IMCR 45258D105 $43.9M 2.06% 1,381,317 SH
13 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $40.3M 1.90% 2,193,981 SH
14 VOR BIOPHARMA INC VOR 929033207 $35.4M 1.67% 1,925,066 SH
15 SAB BIOTHERAPEUTICS INC SABS 78397T202 $31.1M 1.46% 7,967,207 SH
16 INVENTIVA SA IVA 46124U107 $30.9M 1.45% 8,163,191 SH
17 AURA BIOSCIENCES INC AURA 05153U107 $30.5M 1.44% 4,298,248 SH
18 TYRA BIOSCIENCES INC TYRA 90240B106 $25.8M 1.21% 806,986 SH
19 OPUS GENETICS INC IRD 67577R102 $25.0M 1.17% 6,077,084 SH
20 ANIKA THERAPEUTICS INC ANIK 035255108 $21.0M 0.99% 1,435,130 SH
21 SAGIMET BIOSCIENCES INC SGMT 786700104 $19.3M 0.91% 2,500,000 SH
22 ARTIVA BIOTHERAPEUTICS INC ARTV 04317A107 $16.8M 0.79% 1,736,111 SH
23 FAETH THERAPEUTICS INC FTH 81728A207 $15.7M 0.74% 629,467 SH
24 MBX BIOSCIENCES INC MBX 55287L101 $11.0M 0.52% 200,000 SH
25 VERRICA PHARMACEUTICALS INC VRCA 92511W207 $5.7M 0.27% 923,910 SH
26 AGIOS PHARMACEUTICALS INC Call AGIO 00847X104 $3.3M 0.16% 90,000 SH
27 ADMA BIOLOGICS INC Call ADMA 000899104 $2.5M 0.12% 300,000 SH
28 CELLECTAR BIOSCIENCES INC CLRB 15117F880 $1.3M 0.06% 469,998 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $2.13B 28 0001420506-26-001809
2026-03-31 2026-05-15 $1.50B 28 0001420506-26-001039
2025-12-31 2026-02-17 $1.21B 24 0001420506-26-000584
2025-09-30 2025-11-14 $763.5M 18 0001420506-25-003441